echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The listing application of Kelun, a 100 million-level oral hypoglycemic drug, was approved, and Yangzijiang and Shiyao competed for the market

    The listing application of Kelun, a 100 million-level oral hypoglycemic drug, was approved, and Yangzijiang and Shiyao competed for the market

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 9, Kelun's 4-type generic application for linagliptin tablets was approved, becoming the fourth domestic company


    Figure 1: Kelun's latest approved products

    Source: NMPA official website

    Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in patients with type 2 diabetes mellitus as monotherapy or in combination with metformin hydrochloride or with metformin hydrochloride and The combination of sulfonylureas is used to improve glycemic control in patients with type 2 diabetes who cannot effectively control blood sugar with these drugs alone or in combination


    Data shows that Guangdong Sunshine Pharmaceutical won the first domestic imitation of linagliptin tablets as early as 2020.


    Figure 2: 2021E China Urban Physical Pharmacy Terminal Non-insulin Hypoglycemic Drugs Oral TOP20 Variety Pattern

    Source: Minet.


    According to the data of Minet.


    Figure 3: Sales of linagliptin by Boehringer Ingelheim (unit: ten thousand yuan)

    Source: Minet.


    In recent years, Boehringer Ingelheim's linagliptin has maintained a positive growth trend in physical pharmacy terminals in Chinese cities.


    Earlier, Kelun has obtained the production approval for glipizide capsules, empagliflozin tablets, canagliflozin tablets and sitagliptin phosphate tablets.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.